Moderna
-
FDA Approves Updated Covid-19 Vaccines to Address Now Circulating Variants
The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review.
-
Moderna Puts Up $120M to Start Cancer Drug R&D Alliance With Immatics
Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
The Public Health Emergency Is Expiring, So What Is the Future of Covid-19 Vaccines?
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
-
FDA’s Covid-19 Changes Set Stage for the Vaccines to Emulate Seasonal Flu Shots
Older adults and immunocompromised people may now get a second Covid-19 booster shot, according to amendments to the FDA authorizations of the mRNA vaccines. Further changes will be discussed at an advisory committee meeting planned for June.
-
Moderna Signs On a New Partner in Quest for In Vivo mRNA Gene Editing
Moderna is partnering with Life Edit, a subsidiary of ElevateBio that offers a suite of gene-editing technologies. The deal brings together the capabilities of both companies, which aim to develop in vivo gene-editing therapies.Mod
-
Moderna Flu Vax Prompts Response to More Common Strains, But Misses in Influenza B
Moderna’s mRNA vaccine for influenza has early data from a pivotal study showing it met trial goals assessing immune response against the more common strains of the virus, but missed against two less common types. A separate and ongoing Phase 3 study is assessing efficacy.
-
Merck pays Moderna $250M to share equally in cancer vaccine for melanoma
Moderna and Merck have been partners in the development of messenger RNA cancer vaccines since 2016. Merck is deepening the alliance by exercising an option that enables it to share equally in further work on a partnered cancer vaccine for melanoma.
-
FDA authorizes updated Covid-19 boosters to protect against omicron this fall, winter
The FDA has authorized mRNA Covid-19 booster shots designed to protect against the original strain of the novel coronavirus, as well as the two omicron subvariants that are currently driving U.S. caseloads. An advisory committee to the CDC is scheduled to discuss these vaccines and vote on their recommended use on Thursday.
-
Moderna’s Covid-19 vaccine patent suit points to different virus to make infringement case against Pfizer
Moderna is suing Pfizer and BioNTech, claiming they copied its messenger RNA work in developing their Covid-19 vaccine. The company notes that its patented work in respiratory infectious disease began years before the start of the Covid-19 pandemic, when the biotech was pursuing an mRNA vaccine for a different coronavirus.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
U.S. government places $1.74B order for Moderna’s new Covid-19 vaccine boosters
The U.S. government has signed a supply agreement securing 66 million doses of Moderna’s Covid-19 vaccine booster shots, which are designed to address the omicron subvariants driving new cases of infection. The agreement follows a similar supply agreement reached with Pfizer and BioNTech.
-
Feds commit $3.2B to lock in Covid-19 vax supply ahead of fall vaccination campaign
New Covid-19 vaccine booster shots are coming and they’ll include protection against the omicron variant. The U.S. government agreed to a purchasing contract covering 105 million doses of the Pfizer/BioNTech vaccine for a planned vaccination campaign in the fall.
-
Pfizer, Moderna Covid-19 vaccines are now authorized for kids as young as 6 months
Covid-19 vaccines from Pfizer and Moderna now have FDA emergency use authorization for children as young as 6 months old. If the Centers for Disease Control and Prevention signs off on these shots this weekend, these pediatric vaccines could become available for distribution early next week.
-
Alnylam sues Moderna & Pfizer, claiming Covid-19 vaccines infringe lipid patent
Alnylam Pharmaceuticals has proprietary lipid nanoparticle technology used in its FDA-approved RNA therapies. The biotech company claims that the messenger RNA Covid-19 vaccines from Moderna and Pfizer infringe on a patent covering this LNP technology.
-
Concern about Covid-19 variant Omicron centers on spike protein mutations
The new Covid-19 variant, named Omicron, has mutations that could help it evade antibodies produced by the immune system. Scientists are conducting lab tests to better understand this new variant and pharmaceutical companies are testing how existing vaccines, as well as those in development, measure up the new mutations.
-
FDA authorizes Moderna and J&J Covid vaccine boosters, permits ‘mix and match’
The FDA amended emergency use authorization of the Moderna and Johnson & Johnson Covid-19 vaccines, permitting booster shots. But the agency went further and said that a booster shot may be different than the one given for the primary vaccination.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
